{
    "Clinical Trial ID": "NCT00448591",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Bevacizumab",
        "  Participants received bevacizumab 15 mg/kg iv on Day 1 of each 3 week cycle, or 10 mg/kg iv on Day 1 of each 2 week cycle (weekly equivalent dose of 5 mg/kg/week) along with Taxane-based chemotherapy as prescribed"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  patients, >=18 years of age;",
        "  HER-2 negative adenocarcinoma of the breast, with locally recurrent or metastatic disease; (HER-2 positive patients only if previously treated with Herceptin in the adjuvant setting;",
        "  candidates for chemotherapy.",
        "Exclusion Criteria:",
        "  previous chemotherapy for metastatic or locally recurrent breast cancer;",
        "  concomitant hormonal therapy for metastatic or locally recurrent disease;",
        "  concomitant Herceptin therapy for treatment of metastatic or locally recurrent HER-2 positive disease;",
        "  previous radiotherapy for treatment of metastatic disease;",
        "  evidence of CNS metastases."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) Related to Bevacizumab, Death, and AEs of Special Interest (AESIs)",
        "  Adverse events (including laboratory abnormalities) were assessed by the investigator according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) grading systems.",
        "  Time frame: Day 1 of Cycles 1, 2, 3, 4, 5, and 6 up to 6 months after the last bevacizumab infusion",
        "Results 1: ",
        "  Arm/Group Title: Bevacizumab",
        "  Arm/Group Description: Participants received bevacizumab 15 mg/kg iv on Day 1 of each 3 week cycle, or 10 mg/kg iv on Day 1 of each 2 week cycle (weekly equivalent dose of 5 mg/kg/week) along with Taxane-based chemotherapy as prescribed",
        "  Overall Number of Participants Analyzed: 2264",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  Any AE: 95.4",
        "  CTC grade 3, 4 or 5 AE: 57.6",
        "  Bevacizumab-related AE: 64.2",
        "  Any Serious AE: 29.7",
        "  Bevacizumab-related serious SAE: 7.6",
        "  All deaths: 53.1",
        "AESIs: 71.8"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 672/2264 (29.68%)",
        "  Febrile neutropenia * 117/2264 (5.17%)",
        "  Neutropenia * 98/2264 (4.33%)",
        "  Febrile bone marrow aplasia * 14/2264 (0.62%)",
        "  Anaemia * 8/2264 (0.35%)",
        "  Leukopenia * 8/2264 (0.35%)",
        "  Thrombocytopenia * 6/2264 (0.27%)",
        "  Disseminated intravascular coagulation * 3/2264 (0.13%)",
        "  Agranulocytosis * 1/2264 (0.04%)",
        "  Bone marrow failure * 1/2264 (0.04%)"
    ]
}